The abstract is read at the publisher; the summary is JClub's.
Dasatinib in relapsed/refractory T follicular helper cell lymphomas produced a 23.5% overall response rate in 17 evaluable patients, below the 30% prespecified endpoint.
- Why it matters: The trial addresses limited options for TFHL, where TCR signaling mutations and epigenetic changes like TET2 alterations may shape treatment responsiveness.
- What they did: In a multi-center, single-arm phase 2 study (jRCT2031190079), 18 patients received dasatinib and efficacy was assessed by CT-based Lugano criteria 2014, with key secondary analyses including RHOA-mutated disease.
- The result: RHOA p.G17V–associated cases showed a 36.4% ORR, while no responses occurred in mutation-negative patients; exploratory single-cell data linked early progression to high TET2 mutation burden in non-malignant immune cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.